RecruitingNCT05430828

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Sponsor

Federico II University

Enrollment

5,000 participants

Start Date

Mar 7, 2020

Study Type

OBSERVATIONAL

Conditions

Hypercholesterolemia

Summary

Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria1

Patients under PCSK9 inhibitor treatment.

Exclusion Criteria2

Age < 18 years o > 80 years;
Patients who refuse to participate and to sign informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRepatha (evolocumab); Praluent (alirocumab)

Dosage form: Injection

Locations(27)

Ospedali dell'Ovest Vicentino

Arzignano, Italy

University of Bari Aldo Moro

Bari, Italy

University of Campania Luigi Vanvitelli

Caserta, Italy

University Magna Graecia of Catanzaro

Catanzaro, Italy

Presidio Ospedaliero Maria SS Addolorata

Eboli, Italy

Policlinico Riuniti Foggia

Foggia, Italy

Università degli Studi di Genova

Genova, Italy

Ospedale di Lecce

Lecce, Italy

Università degli Studi di Messina

Messina, Italy

Policlinico di Milano Ospedale Maggiore - Fondazione IRCCS Ca' Granda

Milan, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

AORN dei Colli - Ospedale monaldi

Naples, Italy

Federico II University of Naples, Department of Advanced Biomedical Sciences

Naples, Italy

Federico II University of Naples, Department of Translational Medical Sciences

Naples, Italy

University of Naples Federico II, Department of Clinical Medicine and Surgery

Naples, Italy

Azienda Ospedaliero-Universitaria "Maggiore della Carità"

Novara, Italy

Azienda Ospedaliero-Univeristaria di Parma

Parma, Italy

Presidio Ospedaliero Pescara

Pescara, Italy

Ospedale di Rivoli

Rivoli, Italy

Policlinico Tor Vergata

Roma, Italy

Azienda Ospedaliera San Camillo-Forlanini

Roma, Italy

Policlinico Casilino

Roma, Italy

Sapienza University of Rome

Roma, Italy

Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona

Salerno, Italy

Ospedale SS Annunziata A.O.U.

Sassari, Italy

University of Siena

Siena, Italy

Azienda Ospedaliera Ordine Mauriziano Torino

Torino, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05430828

Related Trials

Causes and Natural History of Dyslipidemias

NCT003537821 location

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

NCT075241011 location

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT074777046 locations

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

NCT075818081 location

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT0645177010 locations